Table 1.
Frequency of fVIII domain-specific antibodies in acquired and congenital hemophilia inhibitor patients
| Study | Number of patients | Absolute and relative number of patients with IgG binding to | |||||
|---|---|---|---|---|---|---|---|
| HSA-domain fusion proteins | SHD hpfVIII proteins | ||||||
| A2 | C1 | C2 | A2 | C1 | C2 | ||
| AHA group I, n (%) | 23 | 4 (17) | 12 (52) | 17 (74) | 1 (4) | 5 (22) | 12 (52) |
| AHA group II, n (%) | 92 | 23 (25) | 78 (85) | 61 (66) | 20 (22) | 29 (32) | 49 (53) |
| Total AHA, n (%) | 115 | 27 (23) | 90 (78) | 78 (68) | 21 (18) | 34 (30) | 61 (53) |
| HA group I, n (%) | 33 | 28 (85) | 23 (70) | 31 (94) | 13 (39) | 4 (12) | 18 (55) |
| HA group II, n (%) | 30 | 5 (17) | 13 (43) | 20 (67) | 5 (17) | 0 (0) | 14 (47) |
| Total HA, n (%) | 63 | 33 (52) | 36 (57) | 51 (81) | 18 (29) | 4 (6) | 32 (51) |
| AHA + HA, n (%) | 178 | 60 (34) | 126 (71) | 129 (72) | 39 (22) | 38 (21) | 93 (52) |
The frequency of fVIII domain-specific IgG in patients with AHA and congenital HA and inhibitors to human A2, C1, or C2 domains was measured by ELISA using HSA-fVIII domain fusion proteins and SHD hpfVIII proteins as antigens. For details regarding patient groups and experimental settings, see “Methods”.